1
|
Wu J, Power H, Miranda-Saksena M, Valtchev P, Schindeler A, Cunningham AL, Dehghani F. Identifying HSV-1 Inhibitors from Natural Compounds via Virtual Screening Targeting Surface Glycoprotein D. Pharmaceuticals (Basel) 2022; 15:361. [PMID: 35337158 PMCID: PMC8955139 DOI: 10.3390/ph15030361] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2022] [Revised: 03/07/2022] [Accepted: 03/11/2022] [Indexed: 02/05/2023] Open
Abstract
Herpes simplex virus (HSV) infections are a worldwide health problem in need of new effective treatments. Of particular interest is the identification of antiviral agents that act via different mechanisms compared to current drugs, as these could interact synergistically with first-line antiherpetic agents to accelerate the resolution of HSV-1-associated lesions. For this study, we applied a structure-based molecular docking approach targeting the nectin-1 and herpesvirus entry mediator (HVEM) binding interfaces of the viral glycoprotein D (gD). More than 527,000 natural compounds were virtually screened using Autodock Vina and then filtered for favorable ADMET profiles. Eight top hits were evaluated experimentally in African green monkey kidney cell line (VERO) cells, which yielded two compounds with potential antiherpetic activity. One active compound (1-(1-benzofuran-2-yl)-2-[(5Z)-2H,6H,7H,8H-[1,3] dioxolo[4,5-g]isoquinoline-5-ylidene]ethenone) showed weak but significant antiviral activity. Although less potent than antiherpetic agents, such as acyclovir, it acted at the viral inactivation stage in a dose-dependent manner, suggesting a novel mode of action. These results highlight the feasibility of in silico approaches for identifying new antiviral compounds, which may be further optimized by medicinal chemistry approaches.
Collapse
Affiliation(s)
- Jiadai Wu
- School of Chemical and Biomolecular Engineering, Faculty of Engineering, The University of Sydney, Sydney 2006, Australia; (J.W.); (H.P.); (P.V.); (A.S.)
- Centre for Advanced Food Engineering, The University of Sydney, Sydney 2006, Australia
- Centre for Virus Research, The Westmead Institute for Medical Research, Westmead 2145, Australia;
| | - Helen Power
- School of Chemical and Biomolecular Engineering, Faculty of Engineering, The University of Sydney, Sydney 2006, Australia; (J.W.); (H.P.); (P.V.); (A.S.)
- Centre for Advanced Food Engineering, The University of Sydney, Sydney 2006, Australia
- Bioengineering and Molecular Medicine Laboratory, The Children’s Hospital at Westmead and The Westmead Institute for Medical Research, Westmead 2145, Australia
| | - Monica Miranda-Saksena
- Centre for Virus Research, The Westmead Institute for Medical Research, Westmead 2145, Australia;
| | - Peter Valtchev
- School of Chemical and Biomolecular Engineering, Faculty of Engineering, The University of Sydney, Sydney 2006, Australia; (J.W.); (H.P.); (P.V.); (A.S.)
- Centre for Advanced Food Engineering, The University of Sydney, Sydney 2006, Australia
| | - Aaron Schindeler
- School of Chemical and Biomolecular Engineering, Faculty of Engineering, The University of Sydney, Sydney 2006, Australia; (J.W.); (H.P.); (P.V.); (A.S.)
- Centre for Advanced Food Engineering, The University of Sydney, Sydney 2006, Australia
- Bioengineering and Molecular Medicine Laboratory, The Children’s Hospital at Westmead and The Westmead Institute for Medical Research, Westmead 2145, Australia
| | - Anthony L. Cunningham
- Centre for Virus Research, The Westmead Institute for Medical Research, Westmead 2145, Australia;
| | - Fariba Dehghani
- School of Chemical and Biomolecular Engineering, Faculty of Engineering, The University of Sydney, Sydney 2006, Australia; (J.W.); (H.P.); (P.V.); (A.S.)
- Centre for Advanced Food Engineering, The University of Sydney, Sydney 2006, Australia
| |
Collapse
|
2
|
Leite TOC, Novais JS, de Carvalho BLC, Ferreira VF, Miceli LA, Fraga L, Abrahim-Vieira B, Rodrigues CR, Sá Figueiredo AM, Castro HC, Cunha AC. Synthesis, In Vitro and In Silico Studies of Indolequinone Derivatives against Clinically Relevant Bacterial Pathogens. Curr Top Med Chem 2020; 20:192-208. [DOI: 10.2174/1568026620666191223110518] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2019] [Revised: 11/05/2019] [Accepted: 11/25/2019] [Indexed: 01/09/2023]
Abstract
Background:
According to the World Health Organization, antimicrobial resistance is one of
the most important public health threats of the 21st century. Therefore, there is an urgent need for the
development of antimicrobial agents with new mechanism of action, especially those capable of evading
known resistance mechanisms.
Objective:
We described the synthesis, in vitro antimicrobial evaluation, and in silico analysis of a series
of 1H-indole-4,7-dione derivatives.
Methods:
The new series of 1H-indole-4,7-diones was prepared with good yield by using a copper(II)-
mediated reaction between bromoquinone and β-enamino ketones bearing alkyl or phenyl groups attached
to the nitrogen atom. The antimicrobial potential of indole derivatives was assessed. Molecular
docking studies were also performed using AutoDock 4.2 for Windows. Characterization of all compounds
was confirmed by one- and two-dimensional NMR techniques 1H and 13C NMR spectra [1H, 13C
– APT, 1H x 1H – COSY, HSQC and HMBC], IR and mass spectrometry analysis.
Results:
Several indolequinone compounds showed effective antimicrobial profile against Grampositive
(MIC = 16 µg.mL-1) and Gram-negative bacteria (MIC = 8 µg.mL-1) similar to antimicrobials
current on the market. The 3-acetyl-1-(2,5-dimethylphenyl)-1H-indole-4,7-dione derivative exhibited an
important effect against different biofilm stages formed by a serious hospital life-threatening resistant
strain of Methicillin-Resistant Staphylococcus aureus (MRSA). A hemocompatibility profile analysis
based on in vitro hemolysis assays revealed the low toxicity effects of this new series. Indeed, in silico
studies showed a good pharmacokinetics and toxicological profiles for all indolequinone derivatives,
reinforcing their feasibility to display a promising oral bioavailability. An elucidation of the promising
indolequinone derivatives binding mode was achieved, showing interactions with important sites to biological
activity of S. aureus DNA gyrase. These results highlighted 3-acetyl-1-(2-hydroxyethyl)-1Hindole-
4,7-dione derivative as broad-spectrum antimicrobial prototype to be further explored for treating
bacterial infections.
Conclusion:
The highly substituted indolequinones were obtained in moderate to good yields. The
pharmacological study indicated that these compounds should be exploited in the search for a leading
substance in a project aimed at obtaining new antimicrobials effective against Gram-negative bacteria.
Collapse
Affiliation(s)
- Talita Odriane Custodio Leite
- Universidade Federal Fluminense, Instituto de Quimica, Departamento de Quimica Organica, Programa de Pos- Graduacao em Quimica, 24020-141, Niteroi, Rio de Janeiro, Brazil
| | - Juliana Silva Novais
- Universidade Federal Fluminense, Programas de Pos-Graduacao em Patologia (HUAP) e em Ciencias e Biotecnologia (PPBI), 24020-150, Niteroi, Rio de Janeiro, Brazil
| | - Beatriz Lima Cosenza de Carvalho
- Universidade Federal do Rio de Janeiro, Instituto de Quimica, Departamento de Quimica Organica, 21941-909, Rio de Janeiro, Brazil
| | - Vitor Francisco Ferreira
- Universidade Federal Fluminense, Faculdade de Farmácia, 24241-000, Departamento de Tecnologia Farmaceutica, Niteroi, Rio de Janeiro, Brazil
| | - Leonardo Alves Miceli
- Universidade Federal do Rio de Janeiro, Instituto de Microbiologia Professor Paulo de Goes, Programa de Pos-Graduacao em Ciencias Farmaceuticas e Faculdade de Farmacia, 21941-902, Rio de Janeiro, Brazil
| | - Letícia Fraga
- Universidade Federal do Rio de Janeiro, Laboratorio de Modelagem Molecular e QSAR (MODMOLQSAR), Faculdade de Farmacia, 21941-902, Rio de Janeiro, Brazil
| | - Bárbara Abrahim-Vieira
- Universidade Federal do Rio de Janeiro, Laboratorio de Modelagem Molecular e QSAR (MODMOLQSAR), Faculdade de Farmacia, 21941-902, Rio de Janeiro, Brazil
| | - Carlos Rangel Rodrigues
- Universidade Federal do Rio de Janeiro, Programa de Pos-Graduacao em Ciências Farmaceuticas da Faculdade de Farmacia, 21941-902, Rio de Janeiro, Brazil
| | - Agnes Marie Sá Figueiredo
- Universidade Federal do Rio de Janeiro, Laboratorio de Modelagem Molecular e QSAR (MODMOLQSAR), Faculdade de Farmacia, 21941-902, Rio de Janeiro, Brazil
| | - Helena Carla Castro
- Universidade Federal Fluminense, Programas de Pos-Graduacao em Patologia (HUAP) e em Ciencias e Biotecnologia (PPBI), 24020-150, Niteroi, Rio de Janeiro, Brazil
| | - Anna Claudia Cunha
- Universidade Federal Fluminense, Instituto de Quimica, Departamento de Quimica Organica, Programa de Pos- Graduacao em Quimica, 24020-141, Niteroi, Rio de Janeiro, Brazil
| |
Collapse
|
3
|
Čulenová M, Sychrová A, Hassan STS, Berchová-Bímová K, Svobodová P, Helclová A, Michnová H, Hošek J, Vasilev H, Suchý P, Kuzminová G, Švajdlenka E, Gajdziok J, Čížek A, Suchý V, Šmejkal K. Multiple In vitro biological effects of phenolic compounds from Morus alba root bark. JOURNAL OF ETHNOPHARMACOLOGY 2020; 248:112296. [PMID: 31610262 DOI: 10.1016/j.jep.2019.112296] [Citation(s) in RCA: 35] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/18/2019] [Accepted: 10/09/2019] [Indexed: 05/18/2023]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE Morus alba L. is used in traditional Chinese medicine for the treatment of various diseases, including bacterial infections and inflammation. As a rich source of phenolic compounds, the plant is an object of many phytochemical and pharmacological studies. AIM OF THE STUDY The aim of the study was to isolate and evaluate possible parallel antiviral, antibacterial, and anti-inflammatory activities of phenolic mulberry compounds. MATERIALS AND METHODS Extensive chromatographic separation of mulberry root bark extract and in vitro biological screening of 26 constituents identified promising candidates for further pharmacological research. Selected compounds were screened for anti-infective and anti-inflammatory activities. Antiviral activity was determined by the plaque number reduction assay and by the titer reduction assay, antibacterial using broth microdilution method, and anti-inflammatory activity using COX Colorimetric inhibitor screening assay kit. One compound was evaluated in vivo in carrageenan-induced paw-edema in mice. RESULTS Five prenylated compounds 1, 2, 8, 9, and 11, together with a simple phenolic ester 13, exhibited inhibitory activity against the replication of herpes simplex virus 1 (HSV-1) or herpes simplex virus 2 (HSV-2), with IC50 values ranging from 0.64 to 1.93 μg/mL, and EC50 values 0.93 and 1.61 μg/mL. Molecular docking studies demonstrated the effects of the active compounds by targeting HSV-1 DNA polymerase and HSV-2 protease. In antibacterial assay, compounds 1, 4, 11, and 17 diminished the growth of all of the Gram-positive strains tested, with MIC values of 1-16 μg/mL. The anti-inflammatory ability of several compounds to inhibit cyclooxygenase 2 (COX-2) was tested in vitro, and compound 16 displayed greater activity than the indomethacin, positive control. Mulberrofuran B (11) showed anti-inflammatory activity in vivo against carrageenan-induced paw-edema in mice. CONCLUSIONS Experimental investigation showed promising antiviral, antibacterial, and/or anti-inflammatory activities of the phenolic mulberry constituents, often with multiple inhibitory effects that might be used as a potential source of new medicine.
Collapse
Affiliation(s)
- Marie Čulenová
- Department of Natural Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, CZ-612 42, Brno, Czech Republic.
| | - Alice Sychrová
- Department of Natural Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, CZ-612 42, Brno, Czech Republic
| | - Sherif T S Hassan
- Department of Natural Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, CZ-612 42, Brno, Czech Republic
| | - Kateřina Berchová-Bímová
- Department of Applied Ecology, Faculty of Environmental Sciences, Czech University of Life Sciences Prague, Kamýcká 129, CZ-165 21, Praha 6-Suchdol, Czech Republic
| | - Petra Svobodová
- Department of Natural Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, CZ-612 42, Brno, Czech Republic
| | - Alexandra Helclová
- Department of Natural Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, CZ-612 42, Brno, Czech Republic
| | - Hana Michnová
- Department of Infectious Diseases and Microbiology, Faculty of Veterinary Medicine, University of Veterinary and Pharmaceutical Sciences Brno, CZ-612 42, Brno, Czech Republic
| | - Jan Hošek
- Department of Molecular Biology and Pharmaceutical Biotechnology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, CZ-612 42, Brno, Czech Republic
| | - Hristo Vasilev
- Department of Pharmacognosy, Faculty of Pharmacy, Medical University-Sofia, 2 Dunav str., BG-1000, Sofia, Bulgaria
| | - Pavel Suchý
- Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, CZ-612 42, Brno, Czech Republic
| | - Gabriela Kuzminová
- Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, CZ-612 42, Brno, Czech Republic
| | - Emil Švajdlenka
- Department of Natural Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, CZ-612 42, Brno, Czech Republic
| | - Jan Gajdziok
- Department of Pharmaceutics, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, CZ-612 42, Brno, Czech Republic
| | - Alois Čížek
- Department of Infectious Diseases and Microbiology, Faculty of Veterinary Medicine, University of Veterinary and Pharmaceutical Sciences Brno, CZ-612 42, Brno, Czech Republic
| | - Václav Suchý
- Department of Natural Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, CZ-612 42, Brno, Czech Republic
| | - Karel Šmejkal
- Department of Natural Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, CZ-612 42, Brno, Czech Republic.
| |
Collapse
|
4
|
Psoromic Acid, a Lichen-Derived Molecule, Inhibits the Replication of HSV-1 and HSV-2, and Inactivates HSV-1 DNA Polymerase: Shedding Light on Antiherpetic Properties. Molecules 2019; 24:molecules24162912. [PMID: 31405197 PMCID: PMC6720901 DOI: 10.3390/molecules24162912] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2019] [Revised: 08/07/2019] [Accepted: 08/08/2019] [Indexed: 01/26/2023] Open
Abstract
Psoromic acid (PA), a bioactive lichen-derived compound, was investigated for its inhibitory properties against herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2), along with the inhibitory effect on HSV-1 DNA polymerase, which is a key enzyme that plays an essential role in HSV-1 replication cycle. PA was found to notably inhibit HSV-1 replication (50% inhibitory concentration (IC50): 1.9 μM; selectivity index (SI): 163.2) compared with the standard drug acyclovir (ACV) (IC50: 2.6 μM; SI: 119.2). The combination of PA with ACV has led to potent inhibitory activity against HSV-1 replication (IC50: 1.1 µM; SI: 281.8) compared with that of ACV. Moreover, PA displayed equivalent inhibitory action against HSV-2 replication (50% effective concentration (EC50): 2.7 μM; SI: 114.8) compared with that of ACV (EC50: 2.8 μM; SI: 110.7). The inhibition potency of PA in combination with ACV against HSV-2 replication was also detected (EC50: 1.8 µM; SI: 172.2). Further, PA was observed to effectively inhibit HSV-1 DNA polymerase (as a non-nucleoside inhibitor) with respect to dTTP incorporation in a competitive inhibition mode (half maximal inhibitory concentration (IC50): 0.7 μM; inhibition constant (Ki): 0.3 μM) compared with reference drugs aphidicolin (IC50: 0.8 μM; Ki: 0.4 μM) and ACV triphosphate (ACV-TP) (IC50: 0.9 μM; Ki: 0.5 μM). It is noteworthy that the mechanism by which PA-induced anti-HSV-1 activity was related to its inhibitory action against HSV-1 DNA polymerase. Furthermore, the outcomes of in vitro experiments were authenticated using molecular docking analyses, as the molecular interactions of PA with the active sites of HSV-1 DNA polymerase and HSV-2 protease (an essential enzyme required for HSV-2 replication) were revealed. Since this is a first report on the above-mentioned properties, we can conclude that PA might be a future drug for the treatment of HSV infections as well as a promising lead molecule for further anti-HSV drug design.
Collapse
|